Reports of the prevalence of EGFR mutations in NSCLC ranges from 46.7% in the East Asian population as reported by Liu et al. (8) to 38.4% (range 36.5–40.3%) in China and 14.1% (range 12.7–15.5%) in Europe seen in Zhang et al. (9) and 22% in African Americans enrolled in the Lung Cancer Mutation Consortium (10). This evidence concerns the gene EGFR and lung carcinoma.